Floatz logo

BLEOMYCIN

Hodgkins Lymphoma

National Cancer Institute (NCI)mixturePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
75/ 100
Competitive Position
65/ 100

Competitive context

140 Active assets in the Hodgkins Lymphoma cohort.

Asset / SponsorPhaseRating
Camustine
VIVUS LLC
Phase 2BBB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
ISOCYCLOPHOSPHAMIDE
St. Petersburg State Pavlov Medical University
Phase 3BBB

View all 50 →

Same molecule, other indications

BLEOMYCIN is also rated in:

lymphomaActive
BB
Indicative · Phase 4
71 / 100
View asset →
extragonadal germ cell tumorDormant
BB
Indicative · Phase 3
68 / 100
View asset →
nodular lymphocyte predominant Hodgkin lymphomaDormant
BB
Indicative · Phase 3
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →